Endocrine Abstracts

Introduction: Endogenous subclinical hypercortisolism occurs in 5-30% of patients with adrenal incidentalomas. Adrenal adenoma is the commonest cause of autonomous cortisol secretion (ACS), while primary bilateral macronodular adrenal hyperplasia (PBMAH) is rare. In both, ACS results from activation of the cAMP/PKA pathway. This may be triggered by ligands, other than ACTH, acting upon aberrant G-protein coupled receptors (GPCRs), which may also control locally produced ACTH i...

Objective: Parathyroidectomy (PTx) improves quality of life (QoL) in patients with primary hyperparathyroidism (PHPT). Whether this effect is modified according to the patients’ age is unknown. The aim of this study was to evaluate the impact of age on the effect of PTx on QoL and frailty in patients with PHPT, six months post-PTx. Methods: This was a prospective cohort study, including patients with PHPT, admitted from January 2016 to December 2019...

Introduction: Graves orbitopathy (GO) is an inflammatory condition of the orbital fat and muscles and affect 30-50% of patients with Graves’ disease. The first-line treatment of moderate to severe GO according to EUGOGO is intravenous glucocorticoids, but 20-30% of the cases appear to be corticosteroid resistant or refractory. Promising results have been described with Tocilizumab (TCZ) as a second-line moderate to severe GO treatment.Case presentat...

Purpose: Pheochromocytomas (PCs) and paragangliomas (PGLs) are rare neuroendocrine tumors arising from chromaffin cells of the adrenal medulla and the sympathetic/parasympathetic neural ganglia, respectively. Metastatic PCs/PGLs occur in about 5-26% of cases. Their management and diagnosis still remain a challenge due to their heterogeneity, the absence of guidelines and the few prognostic tools.Aim: The aim of this study was to describe clinical and gen...

Introduction: Idiopathic Isolated Adrenocorticotropic hormone (ACTH) deficiency (IIAD) is a rare cause of secondary adrenal insufficiency. It can present with a variety of clinical symptoms, mainly chronic fatigue and euvolemic hyponatraemia, and may coexist with autoimmune disease, most commonly Hashimoto’s thyroiditis. Radiographically, an empty sella turcica image can be seen. We present 3 cases of isolated ACTH deficiency.Case 1: A 47-year-old w...

Introduction: Ephrin receptors (EPHs) compose the largest known subfamily of receptors tyrosine kinases and are bound and interact with EPHs-interacting proteins (Ephrins). They have a role in tumor growth, invasion, angiogenesis and metastasis of several neoplasms. Aim of the study was to investigate the expression of EPH-A4, -A5, -B2 and -B5 in pituitary lesions. Material and Methods: Our study group consisted of 18 patients (9 males with median age 54...

Introduction: The prevalence of lymph node metastasis from micropapillary thyroid carcinoma (mPTC) in different studies is up to 33%. Preoperative diagnosis of central lymph node (CLN) metastasis is essential for the surgical management of those patients. Prophylactic CLN dissection for patients with mPTC is controversial. Our study aimed to assess the prevalence and the risk factors of LMN metastasis in patients mPTC Methods: We retrospectively study th...

Aim: To explore the metabolic phenotype of Male Obesity-associated Secondary Hypogonadism (MOSH) and following treatment with long-acting intramuscular (IM) testosterone undecanoate.Methods: A prospective observational pilot study on metabolic effects of IM testosterone undecanoate in MOSH (Hypogonadal [HG] group, n=13), including baseline comparisons with controls (Eugonadal [EG] group, n=15). Half the subj...

Aim: To explore the metabolic phenotype of Male Obesity-associated Secondary Hypogonadism (MOSH) and following treatment with long-acting intramuscular (IM) testosterone undecanoate.Methods: A prospective observational pilot study on metabolic effects of IM testosterone undecanoate in MOSH (Hypogonadal [HG] group, n=13), including baseline comparisons with controls (Eugonadal [EG] group, n=15). Half the subj...

Background: Liraglutide is a long-acting glucagon-like peptide-1(GLP-1) receptor agonist that promotes weight loss. The minimum adequate/good response to liraglutide (≥5% weight loss at 3 months) is not achievable in all patients. Currently there are no biomarkers to predict good response. Enhanced postprandial glicentin concentration was recently considered as superior to GLP-1 in predicting weight loss following bariatric surgeries.Objective 1) T...